AxoProtego Therapeutics, LLC is committed to individuals worldwide who suffer from, or are at risk for, “peripheral neuropathy”—a type of nerve damage that results in weakness, numbness, pain, or tingling, usually in the hands or feet. There are many causes of peripheral neuropathy. Our initial focus is neuropathy caused by chemotherapy, also known as Chemotherapy-Induced Peripheral Neuropathy (CIPN). We are dedicated to the discovery, development and commercialization of novel small molecule therapies that protect the neurons from degenerating so that neuropathy never develops.
Our team is currently testing a novel compound, known as EQ-6, initially targeting prevention of peripheral neuropathy in patients undergoing chemotherapy for ovarian cancer. Importantly, AxoProtego’s therapy is distinct from current standard of care, as it protects the neurons and prevents damage before neuropathy can develop. Our therapy may allow patients to complete their recommended chemotherapy protocol without cessation or dose reduction that is often required when CIPN occurs.